Orum Therapeutics, Inc. (KOSDAQ:475830)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Biotechnology	135.42B	75.92M
Biotechnology Growth	178270.49%	-
Total	135.42B	75.92M
Total Growth	178270.49%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Korea	-	75.92M
United States	135.42B	-
Total	135.42B	75.92M
Total Growth	178270.49%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 21, 2026

Data Sources Report a data error